Plasma five-protein risk score for prognostic stratification in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab
We aimed to characterize longitudinal plasma proteomic changes and develop a non-invasive prognostic protein signature for patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab. Paired plasma samples from 71 patients at baseline and after three treatment cycles were analyz...